Drug Metabolism/Pharmacology News

WASHINGTON — Beginning Friday, October 20, Healio Gastroenterology and Liver Disease will provide live coverage from the The Liver Meeting 2017.

Hospital discharges for toxin and drug-induced hepatitis increased significantly between 2001 and 2011 in the U.S., particularly in the south and the west, while rates decreased in the northeast, according to a presentation at the World Congress of Gastroenterology at ACG 2017.

The novel, noninvasive NASH FibroSure test may have utility in monitoring fibrosis risk in patients treated for psoriasis with methotrexate, according to recent findings.

Ibuprofen is one of the most frequent causative agents listed in the Spanish and Latin-American registries of the Drug-Induced Liver Injury Network, according to a recently published study.

Comparative data from the Drug-Induced Liver Injury Network Prospective Study showed that the most common drug-induced liver injury causative agents differ between African-Americans and Caucasians and that African-Americans were more likely to have severe cutaneous reactions and more severe liver injury.

Allena Pharmaceuticals has received an orphan drug designation from the FDA for its investigational product ALLN-177 for the treatment of primary hyperoxaluria and markedly elevated urinary oxalate excretion, according a press release.

Chronic use of cannabinoid derivatives led to a significant increase in cannabinoid hyperemesis syndrome, characterized by episodes of severe nausea and cyclical vomiting, the symptoms of which improve with cannabis cessation, as well as cannabinoid dependency.

The FDA has approved Vantrela ER, an extended release tablet, for patients with severe pain that necessitates long-term, around-the-clock treatment, according to a press release from its manufacturer.

Tenofovir disoproxil fumarate monotherapy was effective and well-tolerated in patients with lamivudine-resistant chronic hepatitis B up to 5 years, according to recent findings published in Journal of Hepatology.